Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana Biotechnology 2018 AGM Presentation

November 16, 2018August 16, 2022 Alterity Therapeutics

2018_11_16 AGM Presentation 2018

2018

Post navigation

Prana AGM Investor Conference Call

Life Biosciences LLC leads strategic investment of up to A$44.5 million in Prana

Related Posts

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

April 10, 2024April 10, 2024

Prana’s PBT2 features as a top 10 global neuroscience project

November 27, 2013August 16, 2022

Prana provides regulatory update for PBT2 for the treatment of Huntington disease

November 2, 2016August 16, 2022

Recent Posts

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065